{"entity":{"type":"insider","cik":"0001642578","url":"/insider/0001642578","json_url":"/insider/0001642578.json","name":"Flagship VentureLabs IV, LLC","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":7,"n_filings":4,"first":"2016-05-27","last":"2019-05-15","span_basis":"filed_date"},"name_variants":[{"name":"Flagship VentureLabs IV, LLC","source":"filing","n_filings":4,"first_seen":"2016-05-27","last_seen":"2019-05-15"}],"transactions":[{"id":8667371,"accession":"0001104659-19-029735","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0001104659-19-029735","line_url":"/filing/0001104659-19-029735#line-12","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Axcella Health Inc.","issuer_ticker":"AXLA","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship Ventures Fund IV-Rx, L.P.; Flagship Ventures Opportunities Fund I, L.P.; AFEYAN NOUBAR; Flagship Ventures Fund 2007, L.P.; Flagship Ventures Fund IV General Partner LLC; Flagship Ventures 2007 General Partner LLC; Flagship Ventures Fund IV, L.P.; Flagship Ventures Opportunities Fund I General Partner LLC; Flagship VentureLabs IV, LLC; KANIA EDWIN M JR","owner_display_name":"Flagship Ventures Fund IV-Rx, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":10,"other_reporting_owners":9,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":500000.0,"shares_display":"500,000","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":10000000.0,"total_display":"10,000,000.00","total_whole":"10,000,000","shares_owned_after":986023.0,"shares_owned_after_display":"986,023","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-13","filed_date":"2019-05-15","scope":"insider"},{"id":6216831,"accession":"0000899243-18-013014","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000899243-18-013014","line_url":"/filing/0000899243-18-013014#line-2","is_derivative":false,"issuer_cik":"0001503559","issuer_name":"Evelo Biosciences, Inc.","issuer_ticker":"EVLO","issuer_name_source":null,"issuer_url":"/issuer/0001503559","owner_cik":null,"owner_name":"Flagship Ventures Fund IV General Partner LLC; Flagship Ventures Fund IV-Rx, L.P.; Flagship VentureLabs IV, LLC; Flagship Ventures Fund IV, L.P.","owner_display_name":"Flagship Ventures Fund IV General Partner LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":281250.0,"shares_display":"281,250","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":4500000.0,"total_display":"4,500,000.00","total_whole":"4,500,000","shares_owned_after":18233403.0,"shares_owned_after_display":"18,233,403","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-05-11","filed_date":"2018-05-15","scope":"insider"},{"id":2906690,"accession":"0001104659-16-131412","txn_seq":10,"anchor":"line-10","filing_url":"/filing/0001104659-16-131412","line_url":"/filing/0001104659-16-131412","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Syros Pharmaceuticals, Inc.","issuer_ticker":"SYRS","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship Ventures Fund IV, L.P.; Flagship Ventures Fund IV General Partner LLC; KANIA EDWIN M JR; AFEYAN NOUBAR; Flagship VentureLabs IV, LLC; Flagship Ventures Fund IV-Rx, L.P.","owner_display_name":"Flagship Ventures Fund IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":400000.0,"shares_display":"400,000","price_per_share":12.5,"price_display":"12.50","price_state":"stated","total_value":5000000.0,"total_display":"5,000,000.00","total_whole":"5,000,000","shares_owned_after":3674660.0,"shares_owned_after_display":"3,674,660","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-07-06","filed_date":"2016-07-07","scope":"insider","n_lines":2},{"id":3109103,"accession":"0001012975-16-001264","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001012975-16-001264","line_url":"/filing/0001012975-16-001264","is_derivative":false,"issuer_cik":"0001222012","issuer_name":"Seres Therapeutics, Inc.","issuer_ticker":"MCRB","issuer_name_source":null,"issuer_url":"/issuer/0001222012","owner_cik":null,"owner_name":"Flagship Ventures Fund 2007, L.P.; Flagship Ventures Fund IV-Rx, L.P.; AFEYAN NOUBAR; Flagship VentureLabs IV, LLC; Flagship Ventures Fund IV, L.P.; Flagship Ventures 2007 General Partner LLC; Flagship Ventures Fund IV General Partner LLC; KANIA EDWIN M JR","owner_display_name":"Flagship Ventures Fund 2007, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock, $0.001 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000000.0,"shares_display":"1,000,000","price_per_share":27.6,"price_display":"27.60","price_state":"stated","total_value":27600000.0,"total_display":"27,600,000.00","total_whole":"27,600,000","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-05-25","filed_date":"2016-05-27","scope":"insider","n_lines":3}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001633070","name":"Axcella Health Inc.","url":"/issuer/0001633070","role":"Ten percent owner","n_filings":1,"first_seen":"2019-05-15","last_seen":"2019-05-15"},{"type":"issuer","type_label":"ISSUER","cik":"0001694665","name":"Evelo Biosciences, Inc.","url":"/issuer/0001694665","role":"Ten percent owner","n_filings":1,"first_seen":"2018-05-15","last_seen":"2018-05-15"},{"type":"issuer","type_label":"ISSUER","cik":"0001556263","name":"Syros Pharmaceuticals, Inc.","url":"/issuer/0001556263","role":"Ten percent owner","n_filings":1,"first_seen":"2016-07-07","last_seen":"2016-07-07"},{"type":"issuer","type_label":"ISSUER","cik":"0001609809","name":"Seres Therapeutics, Inc.","url":"/issuer/0001609809","role":"Ten percent owner","n_filings":1,"first_seen":"2016-05-27","last_seen":"2016-05-27"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001642578","retrieved_at":"2026-08-23T20:19:28+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}